Clinical practice guideline and real-life practice in hepatocellular carcinoma: Korea perspective |
Myung Ji Goh1, Dong Hyun Sinn1, Jong Man Kim2, Min Woo Lee3, Dong Ho Hyun3, Jeong Il Yu4, Jung Yong Hong5, Moon Seok Choi1 |
1Division of Gastroenterology and Hepatology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea 2Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea 3Department of Radiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea 4Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea 5Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea |
Correspondence : |
Moon Seok Choi , Tel: +82-2-3410-3409, Fax: +82-2-3410-6983, Email: drmschoi@gmail.com |
|
Received: November 16, 2022 Revised: December 28, 2022 Accepted: January 1, 2023 |
|
ABSTRACT |
|
Hepatocellular carcinoma (HCC) is a major cause of death in many countries including Korea. To provide useful and sensible advice for clinical management of patients with HCC, the Korean Liver Cancer Association and National Cancer Center (KLCA-NCC) Korea Practice Guideline Revision Committee has recently revised practice guidelines for the management of HCC. However, there are some differences between practice guidelines and real-life clinical practice for several reasons. In this review, we will describe some key recommendations of the 2022 version of practice guidelines and real-life clinical situation in Korea together with a discussion about efforts needed to reduce the gap between practice guidelines and real-life clinical practice. |
KeyWords:
Hepatocellular carcinoma; Practice guidelines; Real-life clinical practice |
|
|